BBIO

BridgeBio Pharma, Inc.

BBIO · CIK 1743881 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$502M
20192025
Net Income−$733M
20192025
Operating CF−$446M
20192025
Free Cash Flow−$447M
20192025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Revenue$0.5B$0.2B$0.0B$0.1B$0.1B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B$0.0B—$0.0B——
Gross Profit———————
R&D Expense$0.5B$0.5B$0.5B$0.4B$0.5B$0.3B$0.2B
SG&A Expense$0.5B$0.3B$0.2B$0.1B$0.2B——
Operating Income$-0.5B$-0.6B$-0.6B$-0.5B$-0.6B$-0.5B$-0.3B
Net Income$-0.7B$-0.5B$-0.7B$-0.5B$-0.6B$-0.5B$-0.3B
EPS (Basic)$-3.78$-2.88$-3.95$-3.26———
EPS (Diluted)$-3.78$-2.88$-3.95$-3.26———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Total Assets$0.9B$0.9B$0.5B$0.6B$1.0B$0.7B$0.6B
Current Assets$0.8B$0.7B$0.5B$0.5B$0.9B$0.6B$0.6B
Cash & Equivalents$0.6B$0.7B$0.4B$0.4B$0.4B$0.4B$0.4B
Total Liabilities$3.0B$2.4B$1.9B$1.9B$1.9B$0.6B$0.2B
Current Liabilities$0.3B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$-2.1B$-1.5B$-1.4B$-1.3B$-0.9B$0.1B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Operating Cash Flow$-0.4B$-0.5B$-0.5B$-0.4B$-0.5B$-0.4B$-0.3B
Investing Cash Flow$-0.0B$0.1B$0.1B$0.5B$-0.2B$-0.1B$-0.2B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.4B$0.7B$0.5B$-0.0B$0.7B$0.4B$0.4B
← Companies